The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis
OncoTargets and Therapy2018Vol. Volume 11, pp. 1105–1115
Citations Over TimeTop 11% of 2018 papers
Junsheng Fan, Zengfei Xia, Xiaoli Zhang, Yuqing Chen, Ruolan Qian, Sihan Liu, Danming You, Jian Zhang, Peng Luo
Abstract
Generally, alectinib is a drug with preferable efficacy and tolerable adverse effects, and it is suitable for the treatment of intracranial metastases.
Related Papers
- → Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance(2014)195 cited
- → Sequential Therapy with Crizotinib and Alectinib in ALK -Rearranged Non–Small Cell Lung Cancer—A Multicenter Retrospective Study(2016)56 cited
- → Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer(2015)28 cited
- → Brigatinib After Progression From Alectinib or Crizotinib: Paving the Way for Treatment Sequencing of ALK Inhibitors in ALK-Positive NSCLC(2021)6 cited
- → A Case of ALK-rearranged Squamous Cell Lung Cancer Accompanied by Severe Liver Dysfunction Caused by Crizotinib but Not Alectinib(2015)4 cited